FCN3 and hepatocellular carcinoma: Notably, the suppressive effects of FCN3 overexpression on both Treg activation and HCC cell growth were reversed by the β-catenin agonist LY2090314, indicating that FCN3 reduced Treg activation by inhibiting the Wnt/β-catenin pathway.